[1]卢倜章.131I治疗甲状腺疾病的研究趋向[J].国际放射医学核医学杂志,2000,24(3):97-100.
　LU Ti-zhang.Current trend of research on 131I therapy for thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(3):97-100.
点击复制

131I治疗甲状腺疾病的研究趋向(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
24
期数:
2000年第3期
页码:
97-100
栏目:
综述
出版日期:
1900-01-01

文章信息/Info

Title:
Current trend of research on 131I therapy for thyroid diseases
作者:
卢倜章
300052 天津, 天津医科大学总医院核医学科
Author(s):
LU Ti-zhang
Department of Nuclear Medicine, General Hospital of Tianjin Medical University, Tianjin 300052, China
关键词:
131I; 甲状腺疾病; 放射性核素治疗
Keywords:
131I; thyroid disease; radionuclide therapy; combined therapy
分类号:
R817. 5
摘要:
目前,131I治疗甲状腺疾病的研究有两个主要趋向。首先,治疗甲状腺疾病的应用范围有所扩大,过去我们仅用131I治疗Graves’病、Plummer氏病或毒性结节性甲状腺肿伴甲亢以及甲状腺癌,而现在还用于一些甲状腺功能正常的甲状腺疾病,例如非毒性多结节甲状腺肿、单纯弥漫性甲状腺肿,甚至甲状腺囊肿。由于131I治疗较其他方法安全、简便,价格便宜,因而扩大其应用范围是十分合理的;第二,131I与其他药物联合应用以减少甲低的发生以及提高其治疗效果,称之为综合性治疗,其所用药物有抗甲状腺药物、肾上腺能β受体阻滞剂、甲状腺激素、糖皮质激素及中医中药等。
Abstract:
At present time, there are two current trends of research on 131I therapy for thyroid diseases. The first is extension of the application on the field of thyroid diseases. Formerly, we use the 131I only on the hyperthyroidism of Graves’ disease,plummer’s disease or toxic nodular goiter as well as thyroid cancer, but now, also for some thyroid diseases with normal thyroid function, such as nontoxic multinodular goiter, simple diffuse goiter even the thyroid cyst. It seems quite rational to use the 131I more widely, because it is really safe, easy and cheaper than others. The second trend is using 131I combined together with other drugs in order to reduce the occurrence of hypothyroidism and enhance the therapeutic effect. Authors call it as combined therapy. Drugs recommended for such therpy are antithyroid drugs, β-adrenergic receptor blocking agents, thyroid hormone, gtucocorticoid as well as Chinese herb drugs and so on.

参考文献/References:

[1] 谭天秩.放射性核素治疗[A].中华人民共和国卫生部医政司.核医学诊断与治疗规范[C].北京:科学出版社, 1997. 280~289.
[2] Howard J D, Donald A M, Michael K. Advances in the management of patients with thyroid diseases[J].Semin Nucl Med, 1995, 25:205~220.
[3] 何广仁.临床与医学[M]. 北京:原子能出版社, 1995.303.
[4] de Groot LJ, Gorman CA, Pinchera A, et al.Therapeutic controversies:radiation and Graves’ ophthalmopathy[J]. J Clin Endocr Metab, 1995, 80:339.
[5] 田蓉.131I治疗甲亢和Graves’眼病[J].国外医学·放射医学核医学分册, 1999, 23(6):251~253.
[6] Beckers C. Radioiodine Therapy, Thyroid International[J]. Brussels, Bergium, 1995.
[7] John CH. Radioiodine Therapy of hyperthyroidism[A] John CH, William CE, Ronaid DN[J]. Nuclear Medicine[C], New York:Thieme Medical Publishers.Inc, 1996. 951~973.
[8] 陈祖培,舒延清. 碘致性甲状腺机能亢进[J].中国地方病杂志, 2000, 19:73~75.
[9] Maurer AH, Charkes D. Radioiodine treatment for nontoxic moltinodalar goiter[J]. J Nucl Med, 1999,40:1313~1316.
[10] Seiler CA, Glaser C, Wagner H E. Thyroid gland surgery in an endemic region[J]. World J Surg, 1995,20:593~596.
[11] Kay TW, d’ Emden MC, Andrews JT, et al. Treatment of nontoxic multinodular goiter with radioactive iodine[J]. Am J Med, 1998, 19~20.
[12] Huysmans AK, Hermus RM, Edebrock M A, et al.Autoimmune hyperthyroidism occurring late after radio-oidine treatment for volume reduction of large multinodular goiters[J]. Thyroid, 1997, 7:535~539.
[13] Milchael AW. Thyroid and thyroid therapy[A].Milchael AW (eds). Textbook of Nuclear Medicine[M]. USA:Raven lippincott, 1998. 153~187.

相似文献/References:

[1]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
　Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[2]刘丽波,罗云霄,王剑峰,等.《放射性甲状腺疾病诊断标准》解读[J].国际放射医学核医学杂志,2012,36(4):204.[doi:10.3760/cma.j.issn.1673-4114.2012.04.002]
　LIU Li-bo,LUO Yun-xiao,WANG Jian-feng,et al.Explanation of Diagnostic Criteria for Radiation Thyroid Diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):204.[doi:10.3760/cma.j.issn.1673-4114.2012.04.002]
[3]张怡,袁卫红.硒与自身免疫性甲状腺疾病[J].国际放射医学核医学杂志,2012,36(6):376.[doi:10.3760/cma.j.issn.1673-4114.2012.06.013]
　ZHANG Yi,YUAN Wei-hong.Selenium and autoimmune thyroid disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):376.[doi:10.3760/cma.j.issn.1673-4114.2012.06.013]
[4]陈跃,黄占文,徐勇,等.加强多学科合作提高甲状腺疾病放射性核素治疗水平[J].国际放射医学核医学杂志,2008,32(6):357.
　CHEN Yue,HUANG Zhan-wen,XU Yong,et al.Intellectual co-operation on improving radionuclide therapy of thyroid disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):357.
[5]罗全勇,朱瑞森.rhTSH在甲状腺疾病治疗中的潜在价值[J].国际放射医学核医学杂志,2005,29(2):63.
　LUO Quan-yong,ZHU Rui-sen.Potential therapeutic uses for rhTSH in thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(3):63.
[6]陆克义,李险峰.甲状腺疾病患者131I治疗后对他人的辐射危害评价[J].国际放射医学核医学杂志,2004,28(5):226.
　LU Ke-yi,LI Xian-feng.Evaluation of radiation exposure from patients with thyroid disease by 131I therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(3):226.
[7]陈跃.131I治疗非毒性甲状腺肿的研究进展[J].国际放射医学核医学杂志,2000,24(3):122.
　CHEN Yue.Radioiodine therapy for nontoxic goiter[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(3):122.
[8]卢倜章.核医学激素测定在甲状腺疾病中的应用[J].国际放射医学核医学杂志,1995,19(2):49.

备注/Memo

备注/Memo:
收稿日期:2000-03-03。
作者简介:卢倜章(1923-),男,浙江杭州人,天津医科大学总医院核医学科教授,主要从事临床核医学尤其是甲状腺疾病的研究。
更新日期/Last Update: 1900-01-01